A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05526716 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1080

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumonia, Pneumococcal

Interventions

BIOLOGICAL: V116
BIOLOGICAL: QIV
BIOLOGICAL: Matching Placebo for V116

Sponsor

Merck Sharp & Dohme LLC